Patent · US Active

Antibody drug conjugates

US9498532B2 · kind B2 · utility

5Cited by

0References

32Claims

0Family size

Assignee

Novartis AG · CH

Inventors

David Bryant Batt · Wayland, US
Seth Ettenberg · Cambridge, US
Nicole HAUBST · Munich, DE
Tiancen Hu · Cambridge, US
David Jenkins · Waltham, US
Engin Toksoz · Munich, DE
Konstantin Petropoulos · Munich, DE
Matthew John Meyer · Framingham, US

Key dates

Filing date	Mar 11, 2014
Grant date	Nov 22, 2016
Priority date	—
Expiry date	Mar 11, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.